CXCR4 and glioblastoma

Anti-Cancer Agents in Medicinal Chemistry

Volumn 16, Issue 1, 2016, Pages 59-74

  Richardson, Peter J ^a  

^a Proximagen Ltd   (United Kingdom)

Author keywords

Cancer stem cell; CXCL12; CXCR4; EMT; Glioblastoma; SDF 1; Signaling

Indexed keywords

CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; ERLOTINIB; LAPATINIB; CHEMOKINE RECEPTOR CXCR4; CXCR4 PROTEIN, HUMAN;

ARTICLE; CANCER STEM CELL; CELL PROLIFERATION; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION; GENETIC TRANSCRIPTION; GLIOBLASTOMA; HUMAN; NONHUMAN; SIGNAL TRANSDUCTION; TUMOR GROWTH; VASCULARIZATION; ANTAGONISTS AND INHIBITORS; CELL DIFFERENTIATION; GENETICS; PATHOLOGY;

CELL DIFFERENTIATION; GLIOBLASTOMA; HUMANS; NEOPLASTIC STEM CELLS; RECEPTORS, CXCR4;

EID: 84947968755     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/1871520615666150824153032     Document Type: Article

References (204)

1. Sottoriva, A.; Spiteri I.; Piccirillo, SG.; Touloumis, A.; Collins, VP.; Marioni, JC.; Curtis, C.; Watts, C.; Tavaré, S. Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics. Proc. Natl. Acad. Sci., USA, 2013 110, 4009-4014.
2. Hattermann, K.; Held-Feindt, J.; Lucius, R.; Muerkoster, S.S. Penfold, M.E.; Schall, T.J.; Mentlein, R. The chemokine receptor CXCR7 is highly expressed in human glioma cells and mediates antiapoptotic effects. Cancer Res., 2010, 70, 3299-308.
3. Sun, X.; Cheng, G.; Hao, M.; Zheng, J.; Zhou, X.; Zhang, J.; Taichman, R.S.; Pienta, K.J.; Wang, J. CXCL12 /CXCR4 / CXCR7 chemokine axis and cancer progression. Cancer Metastasis Rev., 2010, 29, 709-722.
4. Würth, R.; Bajetto, A.; Harrison, J.K.; Barbieri, F.; Florio, T. CXCL12 modulation of CXCR4 and CXCR7 activity in human glioblastoma stem-like cells and regulation of the tumor microenvironment. Front Cell Neurosci., 2014, 8,144.
5. Hattermann, K.; Mentlein, R. An infernal trio: The chemokine CXCL12 and its receptors CXCR4 and CXCR7 in tumor biology. Ann. Anat., 2013, 195(2), 103-110.
6. Burger, J.A.; Kipps, T.J. CXCR4: A key receptor in the crosstalk between tumor cells and their microenvironment. Blood, 2006, 107, 1761-1767.
7. Lapidot, T.; Kollet, O. The essential roles of the chemokine SDF-1 and its receptor CXCR4 in human stem cell homing and repopulation of transplanted immune-deficient NOD/SCID and NOD/SCID/B2m(null) mice. Leukemia, 2002, 16, 1992-2003.
8. Petit, I.; Jin, D.; Rafii, S. The SDF-1-CXCR4 signaling pathway: A molecular hub modulating neo-angiogenesis. Trends Immunol., 2007, 28, 299-307.
9. Kucia, M.; Jankowski, K.; Reca, R.; Wysoczynski, M.; Bandura, L.; Allendorf, D.J.; Zhang, J.; Ratajczak, J.; Ratajczak, M.Z. CXCR4-SDF-1 signalling, locomotion, chemotaxis and adhesion. J. Mol. Histol., 2004, 35, 233-245.
10. Wojakowski, W.; Tendera, M.; Zebzda, A.; Michalowska, A.; Majka, M.; Kucia, M.; Maslankiewicz, K.; Wyderka, R.; Król, M.; Ochala, A.; Kozakiewicz, K.; Ratajczak, M.Z. Mobilization of CD34(+), CD117(+), CXCR4(+), c-met(+) stem cells is correlated with left ventricular ejection fraction and plasma NT-proBNP levels in patients with acute myocardial infarction. Eur. Heart J., 2006, 27, 283-289.
11. Kucia, M.; Zhang, Y.P.; Reca, R.; Wysoczynski, M.; Machalinski, B.; Majka, M.; Ildstad, S.T.; Ratajczak, J.; Shield,s C.B.; Ratajczak, M.Z. Cells enriched in markers of neural tissue-committed stem cells reside in the bone marrow and are mobilized into the peripheral blood following stroke. Leukemia, 2006, 20, 18-28.
12. Paczkowska, E.; Kucia, M.; Koziarska, D.; Halasa, M.; Safranow, K.; Masiuk, M.; Karbicka, A.; Nowik, M.; Nowacki, P.; Ratajczak, M.Z.; Machalinski, B. Clinical evidence that very small embryoniclike stem cells are mobilized into peripheral blood in patients after stroke. Stroke, 2009, 40, 1237-1244.
13. Petersen, B.E.; Bowen, W.C.; Patrene, K.D.; Mars, W.M.; Sullivan, A.K.; Murase, N.; Boggs, S.S.; Greenberger, J.S.; Goff, J.P. Bone marrow as a potential source of hepatic oval cells. Science, 1999, 284, 1168-1170.
14. Tögel, F.; Isaac, J.; Hu, Z.; Weiss, K.; Westenfelder, C. Renal SDF-1 signals mobilization and homing of CXCR4-positive cells to the kidney after ischemic injury. Kidney Int., 2005, 67, 1772-1784.
15. Kale, S.; Karihaloo, A.; Clark, P.R.; Kashgarian, M.; Krause, D.S.; Cantley, LG. Bone marrow stem cells contribute to repair of the ischemically injured renal tubule. J. Clin. Invest., 2003, 112, 42-49.
16. Gomperts, B.N.; Belperio, J.A.; Rao, P.N.; Randell, S.H.; Fishbein, M.C.; Burdick, M.D.; Strieter, R.M. Circulating progenitor epithelial cells traffic via CXCR4/CXCL12 in response to airway injury. J. Immunol., 2006, 176, 1916-1927.
17. Long, M.A.; Corbel, S.Y.; Rossi, F.M. Circulating myogenic progenitors and muscle repair. Semin. Cell Dev. Biol., 2005, 16, 632-640.
18. Hess, D.; Li, L.; Martin, M.; Sakano, S.; Hill, D.; Strutt, B. Thyssen, S.; Gray, D.A.; Bhatia, M. Bone marrow-derived stem cells initiate pancreatic regeneration. Nat. Biotechnol., 2003, 21, 763-770.
19. DiPersio, J.F.; Micallef, I.N.; Stiff, P.J.; Bolwell, B.J.; Maziarz, R.T.; Jacobsen, E.; Nademanee, A.; McCarty, J.; Bridger, G.; Calandra, G. 3101 Investigators. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma. J. Clin. Oncol., 2009, 27, 4767-4773.
20. Nie, Y.; Han, Y.C.; Zou, Y.R. CXCR4 is required for the quiescence of primitive hematopoietic cells. J. Exp. Med., 2008, 205(4), 777-783.
21. Tzeng, Y.S.; Li, H.; Kang, Y.L.; Chen, W.C.; Cheng, W.C.; Lai, D.M. Loss of Cxcl12/Sdf-1 in adult mice decreases the quiescent state of hematopoietic stem/progenitor cells and alters the pattern of hematopoietic regeneration after myelosuppression. Blood, 2011, 117(2), 429-439.
22. Krathwohl, M.D.; Kaiser, J.L. Chemokines promote quiescence and survival of human neural progenitor cells. Stem Cells, 2004, 22(1), 109-118.
23. Dimova, N.; Wysoczynski, M.; Rokosh, G. Stromal cell derived factor-1α promotes C-Kit+ cardiac stem/progenitor cell quiescence through casein kinase 1α and GSK3β. Stem Cells, 2014, 32(2), 487-499.
24. Hall, J.M.; Korach, K.S. Stromal cell-derived factor 1, a novel target of estrogen receptor action, mediates the mitogenic effects of estradiol in ovarian and breast cancer cells. Mol. Endocrinol., 2003, 17, 792-803.
25. Taichman, R.S.; Cooper, C.; Keller, ET.; Pienta, K.J. Taichman NS, McCauley LK. () Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res., 2002, 62, 1832-1837.
26. Darash-Yahana, M.; Pikarsky, E.; Abramovitch, R.; Zeira, E.; Pal, B.; Karplus, R.; Beider, K.; Avniel, S.; Kasem, S.; Galun, E.; Peled, A. Role of high expression levels of CXCR4 in tumor growth, vascularization, and metastasis. FASEB J., 2004, 18(11), 1240-1242.
27. Kaifi, J.T.; Yekebas, E.F.; Schurr, P.; Obonyo, D.; Wachowiak, R.; Busch, P.; Heinecke, A.; Pantel, K.; Izbicki, J.R. Tumor-cell homing to lymph nodes and bone marrow and CXCR4 expression in esophageal cancer. J. Natl. Cancer Inst., 2005, 97, 1840-1847.
28. Balkwill, F. Cancer and the chemokine network. Nat. Rev. Cancer, 2004, 4, 540-550.
29. Cojoc, M.; Peitzsch, C.; Trautmann, F.; Polishchuk, L. Telegeev G.D.; Dubrovska A. Emerging targets in cancer management: Role of the CXCL12/CXCR4 axis. Onco. Targ. Ther., 2013, 30, 1347-1361.
30. Trautmann, F.; Cojoc, M.; Kurth, I.; Melin, N.; Bouchez, L.C.; Dubrovska, A.; Peitzsch, C. CXCR4 as biomarker for radioresistant cancer stem cells. Int. J. Radiat. Biol., 2014, 90(8), 687-699.
31. Scala, S.; Ottaiano, A.; Ascierto, P.A. Expression of CXCR4 predicts poor prognosis in patients with malignant melanoma. Clin. Cancer Res., 2005, 11, 1835-1841.
32. Wang, L.; Chen, W.; Gao, L.; Yang, Q.; Liu, B.; Wu, Z.; Wang, Y.; Sun, Y. High expression of CXCR4, CXCR7 and SDF-1 predicts poor survival in renal cell carcinoma.World J. Surg. Oncol., 2012, 10, 212-219.
33. Gassenmaier, M.; Chen, D.; Buchner, A.; Henkel, L.; Schiemann, M.; Mack, B.; Schendel, D.J.; Zimmermann, W.; Pohla, H. CXC chemokine receptor 4 is essential for maintenance of renal cell carcinoma-initiating cells and predicts metastasis. Stem Cells, 2013, 31(8), 1467-1476.
34. He, H.; Wang, C.; Shen, Z.; Fang, Y.; Wang, X.; Chen, W.; Liu, F.; Qin, X.; Sun, Y. Upregulated expression of C-X-C chemokine receptor 4 is an independent prognostic predictor for patients with gastric cancer. PLoS One, 2013, 8, e71864.
35. Zhang, S.S.; Han, Z.P.; Jing, Y.Y.; Tao, S.F.; Li, T.J.; Wang, H.; Wang, Y.; Li, R.; Yang, Y.; Zhao, X.; Xu, X.D.; Yu, E.D.; Rui, Y.C.; Liu, H.J.; Zhang, L.; Wei, L.X. CD133(+)CXCR4(+) colon cancer cells exhibit metastatic potential and predict poor prognosis of patients. BMC Med., 2012, 10, 85.
36. Wehler, T.; Wolfert, F.; Schimanski, C.C.; Gockel, I.; Herr, W.; Biesterfeld, S.; Seifert, J.K.; Adwan, H.; Berger, M.R.; Junginger, T.; Galle, P.R.; Moehler, M. Strong expression of chemokine receptor CXCR4 by pancreatic cancer correlates with advanced disease. Oncol. Rep., 2006, 16(6), 1159-1164.
37. Liang, J.J.; Zhu, S.; Bruggeman, R. High levels of expression of human stromal cell-derived factor-1 are associated with worse prognosis in patients with stage II pancreatic ductal adenocarcinoma. Cancer Epidemiol. Biomarkers Prev., 2010, 19, 2598-2604.
38. Maréchal, R.; Van, Laethem, J.L. Towards a tailored therapy in pancreatic cancer. Acta Gastroenterol. Belg., 2013, 76, 49-56.
39. Akashi, T.; Koizumi, K.; Tsuneyama, K.; Saiki, I.; Takano, Y.; Fuse, H. Chemokine receptor CXCR4 expression and prognosis in patients with metastatic prostate cancer. Cancer Sci., 2008, 99, 539-542
40. Bian, X.; Xiao, H.; Yang, S.; Wang, J.M. Neurosurgery, 2008, 63, E820.
41. Stevenson, C.B.; Ehtesham, M.; McMillan, K.M.; Valadez, J.G.; Edgeworth, M.L.; Price, R.R.; Abel, T.W.; Mapara, K.Y.; Thompson, R.C. CXCR4 expression is elevated in glioblastoma multiforme and correlates with an increase in intensity and extent of peritumoral T2-weighted magnetic resonance imaging signal abnormalities. Neurosurgery, 2008, 63, 560-569.
42. Komatani, H.; Sugita, Y.; Arakawa, F.; Ohshima, K.; Shigemori, M. Expression of CXCL12 on pseudopalisading cells and proliferating microvessels in glioblastomas: an accelerated growth factor in glioblastomas. Int. J. Oncol., 2009, 34, 665-672.
43. Liu, G.; Yuan, X.; Zeng, Z.; Tunici, P.; Ng, H.; Abdulkadir, I.R.; Lu, L.; Irvin, D.; Black, K.L.; Yu, J.S. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol. Cancer, 2006, 5, 67.
44. Zagzag, D.; Lukyanov, Y.; Lan, L.; Ali, M.A.; Esencay, M.; Mendez, O.; Yee, H.; Voura, E.B.; Newcomb, E.W. Hypoxiainducible factor 1 and VEGF upregulate CXCR4 in glioblastoma: implications for angiogenesis and glioma cell invasion. Lab Invest., 2006, 86, 1221-1232.
45. Fenton, T.R.; Nathanson, D.; Ponte de Albuquerque, C.; Kuga, D.; Iwanami, A.; Dang, J.; Yang, H.; Tanaka, K.; Oba-Shinjo, S.M.; Uno, M.; Inda, M.M.; Wykosky, J.; Bachoo, R.M.; James, C.D.; DePinho, R.A.; Vandenberg, S.R.; Zhou, H.; Marie, S.K. Mischel P.S.; Cavenee, W.K.; Furnari, F.B. Resistance to EGF receptor inhibitors in glioblastoma mediated by phosphorylation of the PTEN tumor suppressor at tyrosine 240. Proc. Natl. Acad. Sci. U S A, 2012, 109(35), 14164-14169.
46. Zagzag, D.; Krishnamachary, B.; Yee, H.; Okuyama, H.; Chiriboga, L.; Ali, M.A.; Melamed, J.; Semenza, G.L. Stromal cellderived factor-1alpha and CXCR4 expression in hemangioblastoma and clear cell-renal cell carcinoma: von Hippel-Lindau loss-offunction induces expression of a ligand and its receptor. Cancer Res., 2005, 65, 6178-6188.
47. Zagzag, D.; Esencay, M.; Mendez, O.; Yee, H.; Smirnova, I.; Huang, Y. Hypoxia-and vascular endothelial growth factorinduced stromal cell derived factor-1alpha/CXCR4 expression in glioblastomas: One plausible explanation of Scherer's structures. Am. J. Pathol., 2008, 173, 545-560.
48. Rempel, S.A.; Dudas, S.; Ge, S.; Gutierrez, J.A. Identification and localization of the cytokine SDF-1 and its receptor, CXC chemokine receptor 4, to regions of necrosis and angiogenesis in human glioblastoma. Clin. Cancer Res., 2000, 6, 102-11.
49. Sciaccaluga, M.; D'Alessandro, G.; Pagani, F.; Ferrara, G.; Lopez, N.; Warr, T.; Gorello, P.; Porzia, A.; Mainiero, F.; Santoro, A.; Esposito, V.; Cantore, G.; Castigli, E.; Limatola, C. Functional cross talk between CXCR4 and PDGFR on glioblastoma cells is essential for migration. PLoS One, 2013, 8, e73426.
50. Sciaccaluga, M.; Fioretti, B.; Catacuzzeno, L.; Pagani, F.; Bertollini, C.; Rosito, M.; Catalano, M.; D'Alessandro, G.; Santoro, A.; Cantore, G.; Ragozzino, D.; Castigli, E.; Franciolini, F.; Limatola, C. CXCL12-induced glioblastoma cell migration requires intermediate conductance Ca2+-activated K+ channel activity. Am. J .Physiol. Cell Physiol., 2010, 299, C175-184.
51. Joy, A.M.; Beaudry, C.E.; Tran, N.L.; Ponce, F.A.; Holz, D.R.; Demuth, T.; Berens, M.E. Migrating glioma cells activate the PI3-K pathway and display decreased susceptibility to apoptosis. J Cell Sci., 2003, 116, 4409-4417.
52. Mariani, L.; Beaudry, C.; McDonough, W.S.; Hoelzinger, D.B.; Demuth, T.; Ross, K.R.; Berens, T.; Coons, S.W.; Watts, G.; Trent, J.M.; Wei, J.S.; Giese, A.; Berens, M.E. Glioma cell motility is associated with reduced transcription of proapoptotic and proliferation genes: A cDNA microarray analysis. J. Neurooncol., 2001, 53, 161-176.
53. Ehtesham, M.; Winston, J.A.; Kabos, P.; Thompson, R.C. CXCR4 expression mediates glioma cell invasiveness. Oncogene, 2006, 25, 2801-2806.
54. Tabouret, E.; Tchoghandjian, A.; Denicolai, E.; Delfino, C.; Metellus, P.; Padovani, L.; Nanni, I.; Barrie, M.; Boucard, C.; Ouafik, L.; Figarella-Branger, D.; Chinot, O. Angiogenic switch from VEGFR2/HF1a in newly diagnosed glioblastoma to CXCR4-SDF-1 pathway in recurrent paired tumour after radiotherapy and temozolomide. Neuro. Oncol., 2014, 16, S5-S7.
55. Olumi, A.F.; Grossfeld, G.D.; Hayward, S.W.; Carroll, P.R.; Tlsty, T.D.; Cunha, G.R. Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res., 1999, 59, 5002-5011.
56. Orimo, A.; Gupta, P.B.; Sgroi, D.C.; Arenzana-Seisdedos, F.; Delaunay, T.; Naeem, R.; Carey, V.J.; Richardson, A.L.; Weinberg, R.A. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell, 2005, 121, 335-348.
57. Hermann, P.C.; Huber, S.L.; Herrler, T.; Aicher, A.; Ellwart, J.W.; Guba, M.; Bruns, C.J.; Heeschen. C. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell, 2007, 1, 313-23.
58. Li, X.; Li, P.; Chang, Y.; Xu, Q.; Wu, Z.; Ma, Q.; Wang, Z. The SDF-1/CXCR4 axis induces epithelial-mesenchymal transition in hepatocellular carcinoma. Mol. Cell Biochem., 2014, 392(1-2), 77-84.
59. Mimeault, M.; Batra, S.K. New advances on critical implications of tumor-and metastasis initiating cells in cancer progression, treatment resistance and disease recurrence. Histol. Histopathol., 2010, 25, 1057-1073.
60. Ghiaur, G.; Gerber, J.; Jones, R.J. Concise review: Cancer stem cells and minimal residual disease. Stem Cells, 2012, 30, 89-93.
61. Vila-Coro, A.J.; Rodríguez-Frade, J.M.; Martín, D.E.; Ana, A.; Moreno-Ortíz, M.C.; Martínez-A, C.; Mellado, M. The chemokine SDF-1alpha triggers CXCR4 receptor dimerization and activates the JAK/STAT pathway. FASEB J., 1999 13(13), 1699-1710.
62. Ratajczak, M.Z.; Zuba-Surma, E.; Kucia, M.; Reca, R.; Wojakowski, W.; Ratajczak, J. The pleiotropic effects of the SDF-1-CXCR4 axis in organogenesis, regeneration and tumorigenesis. Leukemia, 2006, 20, 1915-1924.
63. Chow, L.M.; Endersby, R.; Zhu, X.; Rankin, S.; Qu, C.; Zhang, J.; Broniscer, A.; Ellison, D.W.; Baker, S.J. Cooperativity within and among Pten, p53, and Rb pathways induces high-grade astrocytoma in adult brain. Cancer Cell, 2011, 19, 305-316.
64. Gupta, P.B.; Fillmore, C.M.; Jiang, G.; Shapira, S.D.; Tao, K.; Kuperwasser, C.; Lander, E.S. Stochastic state transitions give rise to phenotypic equilibrium in populations of cancer cells. Cell, 2011, 146, 633-644.
65. Medema, J.P. Cancer stem cells: The challenges ahead. Nat. Cell Biol., 2013, 15(4), 338-344.
66. Pattabiraman, D.R.; Weinberg, R.A. Tackling the cancer stem cells-what challenges do they pose? Nat. Rev. Drug Discov., 2014, 13(7), 497-512.
67. Scheel, C.; Eaton, E.N.; Li, S.H.; Chaffer, C.L.; Reinhardt, F.; Kah, K.J.; Bell, G.; Guo, W.; Rubin, J.; Richardson, A.L.; Weinberg, R.A. Paracrine and autocrine signals induce and maintain mesenchymal and stem cell states in the breast. Cell, 2011, 145(6), 926-940
68. Barone, A.; Sengupta, R.; Warrington, N.M.; Smith, E.; Wen, P.Y.; Brekken, R.A.; Romagnoli, B.; Douglas, G.; Chevalier, E.; Bauer, M.P.; Dembowsky, K.; Piwnica-Worms, D.; Rubin, J.B. Combined VEGF and CXCR4 antagonism targets the GBM stem cell population and synergistically improves survival in an intracranial mouse model of glioblastoma. Oncotarget, 2014 5(20), 9811-9822.
69. Salmaggi, A.; Boiardi, A.; Gelati, M.; Russo, A.; Calatozzolo, C.; Ciusani, E.; Sciacca, F.L.; Ottolina, A.; Parati, E.A.; La, Porta, C.; Alessandri, G.; Marras, C.; Croci, D.; De Rossi, M. Glioblastomaderived tumorospheres identify a population of tumor stem-like cells with angiogenic potential and enhanced multidrug resistance phenotype. Glia, 2006, 54(8), 850-860.
70. Schulte, A.; Günther, H.S.; Phillips, H.S.; Kemming, D.; Martens, T.; Kharbanda, S.; Soriano, R.H.; Modrusan, Z.; Zapf, S.; Westphal, M.; Lamszus, K. A distinct subset of glioma cell lines with stem cell-like properties reflects the transcriptional phenotype of glioblastomas and overexpresses CXCR4 as therapeutic target. Glia, 2011, 59(4), 590-602.
71. Ping, Y.F.; Yao, X.H.; Jiang, J.Y.; Zhao, L.T.; Yu, S.C.; Jiang, T.; Lin, M.C.; Chen, J.H.; Wang, B.; Zhang, R.; Cui, Y.H.; Qian, C.; Wang, J.M.; Bian, X.W. The chemokine CXCL12 and its receptor CXCR4 promote glioma stem cell-mediated VEGF production and tumour angiogenesis via PI3K/AKT signaling. J. Pathol., 2011, 224, 344-354.
72. Cheng, L.; Huang, Z.; Zhou, W.; Wu, Q.; Donnola, S.; Liu, J.K.; Fang, X.; Sloan, A.E.; Mao, Y.; Lathia, J.D.; Min, W.; McLendon, R.E.; Rich, J.N.; Bao, S. Glioblastoma stem cells generate vascular pericytes to support vessel function and tumor growth. Cell, 2013, 153, 139-152.
73. Liu, C.; Pham, K.; Luo, D.; Reynolds, B.A.; Hothi, P.; Foltz, G.; Harrison, J.K. Expressionand functional heterogeneity of chemokine receptors CXCR4 and CXCR7 in primary patientderived glioblastoma cells. PLoS One, 2013, 8, e59750.
74. Lee, C.C.; Lai, J.H.; Hueng, D.Y.; Ma, H.I.; Chung, Y.C.; Sun, Y.Y.; Tsai, Y.J.; Wu, W.B.; Chen, C.L. Disrupting the CXCL12/CXCR4 axis disturbs the characteristics of glioblastoma stem-like cells of rat RG2 glioblastoma. Cancer Cell Int., 2013, 13, 85.
75. Gatti, M.; Pattarozzi, A.; Bajetto, A.; Würth, R.; Daga, A.; Fiaschi P.; Zona, G.; Florio, T.; Barbieri, F. Inhibition of CXCL12/CXCR4 autocrine/paracrine loop reduces viability of human glioblastoma stem-like cells affecting self-renewal activity. Toxicology, 2013, 314, 209-220.
76. Ehtesham, M.; Mapara, K.Y.; Stevenson, C.B.; Thompson, R.C. CXCR4 mediates the proliferation of glioblastoma progenitor cells Cancer Lett., 2009, 274, 305-312.
77. Zheng, X.; Xie, Q.; Li, S.; Zhang, W. CXCR4-positive subset of glioma is enriched for cancer stem cells. Oncol. Res., 2012, 19, 555-561.
78. Bajetto, A.; Barbieri, F.; Dorcaratto, A. Expression of CXC chemokine receptors 1-5 and their ligands in human glioma tissue: Role of CXCR4 and SDF-1 in glioma cell proliferation and migration. Neurochem. Int., 2006 49, 423-432.
79. Brown, J.M. Inhibiting vasculogenesis after radiation: A new paradigm to improve local control by radiotherapy. Semin. Radiat. Oncol., 2013, 23, 281-287.
80. Brown, JM. Vasculogenesis: A crucial player in the resistance of solid tumours to radiotherapy. Br. J. Radiol., 2014, 87(1035), 20130686.
81. Teicher, B.A.; Fricker, S.P. CXCL12 (SDF-1)/CXCR4 pathway in cancer. Clin. Cancer Res., 2010, 16(11), 2927-2931.
82. Jung, M.J.; Rho, J.K.; Kim, Y.M.; Jung, J.E.; Jin, Y.B.; Ko, Y.G.; Lee, J.S.; Lee, S.J.; Lee, J.C.; Park, M.J. Upregulation of CXCR4 is functionally crucial for maintenance of stemness in drug-resistant non-small cell lung cancer cells. Oncogene, 2013, 32, 209-221.
83. Jin, Z.; Zhao, C.; Han, X.; Han, Y. Wnt5a promotes ewing sarcoma cell migration through upregulating CXCR4 expression. BMC Cancer, 2012, 12, 48.
84. Sengupta, R.; Dubuc, A.; Ward, S.; Yang, L.; Northcott, P.; Woerner, BM.; Kroll, K.; Luo, J.; Taylor, M.D.; Wechsler-Reya, R.J.; Rubin, J.B. CXCR4 activation defines a new subgroup of Sonic hedgehog-driven medulloblastoma. Cancer Res., 2012, 72, 122-123.
85. Kukreja, P.; Abdel-Mageed, A.B.; Mondal, D.; Liu, K.; Agrawal, K.C. Up-regulation of CXCR4 expression in PC-3 cells by stromalderived factor-1alpha (CXCL12) increases endothelial adhesion and transendothelial migration: Role of MEK/ERK signaling pathway-dependent NF-kappaB activation. Cancer Res., 2005 65(21), 9891-9898.
86. Lasham, A.; Print, C.G.; Woolley, A.G.; Dunn, S.E.; Braithwaite, A.W. YB-1: Oncoprotein, prognostic marker and therapeutic target? Biochem. J., 2013 449(1), 11-23.
87. Basaki, Y.; Hosoi, F.; Oda, Y.; Fotovati, A.; Maruyama, Y.; Oie, S.; Ono, M.; Izumi, H.; Kohno, K.; Sakai, K.; Shimoyama, T.; Nishio, K.; Kuwano, M. Akt-dependent nuclear localization of Y-box-binding protein 1 in acquisition of malignant characteristics by human ovarian cancer cells. Oncogene, 2007 26(19), 2736-2746.
88. Do Carmo, A.; Patricio, I.; Cruz, M,T.; Carvalheiro, H.; Oliveira, C.R.; Lopes, M,C. CXCL12/CXCR4 promotes motility and proliferation of glioma cells. Cancer Biol. Ther., 2010, 9, 56-65.
89. Conley-Lacomb, M.K.; Saliganan, A.; Kandagatla, P.; Chen, Y.Q.; Cher, M.L.; Chinni, S.R. PTEN loss mediated Akt activation promotes prostate tumor growth and metastasis via CXCL12/ CXCR4 signaling. Mol. Cancer, 2013, 12, 85.
90. Moriuchi, M.; Moriuchi, H.; Margolis, D.M.; Fauci, A.S. USF/c-Myc enhances, while Yin-Yang 1 suppresses, the promoter activity of CXCR4, a coreceptor for HIV-1 entry. J. Immunol., 1999, 162(10), 5986-5992.
91. Katoh, M.; Katoh, M. Integrative genomic analyses of CXCR4: transcriptional regulation of CXCR4 based on TGFbeta, Nodal, Activin signaling and POU5F1, FOXA2, FOXC2, FOXH1, SOX17, and GFI1 transcription factors. Int. J. Oncol., 2010 36, 415-420.
92. Dunn, L.K.; Mohammad, K.S.; Fournier, P.G.; McKenna, C.R.; Davis, H.W.; Niewolna, M.; Peng, X.H.; Chirgwin, J.M.; Guise, T.A. Hypoxia and TGF-beta drive breast cancer bone metastases through parallel signaling pathways in tumor cells and the bone microenvironment. PLoS One, 2009, 4(9), e6896.
93. Chu, C.Y.; Sheen, Y.S.; Cha, S.T.; Hu, Y.F.; Tan, C.T.; Chiu, H.C.; Chang, C.C.; Chen, M,W.; Kuo, M.L.; Jee, S.H. Induction of chemokine receptor CXCR4 expression by transforming growth factor-β1 in human basal cell carcinoma cells. J. Dermatol. Sci., 2013 72(2), 123-133.
94. Maroni, P.; Bendinelli, P.; Matteucci, E.; Desiderio, M.A. HGF induces CXCR4 and CXCL12-mediated tumor invasion through Ets1 and NF-kappaB. Carcinogenesis, 2007 28(2), 267-79.
95. Fotovati, A.; Abu-Ali, S.; Wang, P.S.; Deleyrolle, L.P.; Lee, C.; Triscott, J.; Chen, J.Y.; Franciosi, S.; Nakamura, Y.; Sugita, Y.; Uchiumi, T.; Kuwano, M.; Leavitt, B.R.; Singh, S.K.; Jury, A.; Jones, C.; Wakimoto, H.; Reynolds, B.A.; Pallen, C.J.; Dunn, S.E. YB-1 bridges neural stem cells and brain tumor-initiating cells via its roles in differentiation and cell growth. Cancer Res., 2011, 71(16), 5569-5578.
96. Archibald, K.M.; Kulbe, H.; Kwong, J.; Chakravarty, P.; Temple, J.; Chaplin, T.; Flak, M.B.; McNeish, I.A.; Deen, S.; Brenton, J.D.; Young, B.D.; Balkwill, F. Sequential genetic change at the TP53 and chemokine receptor CXCR4 locus during transformation of human ovarian surface epithelium. Oncogene, 2012, 31, 4987-4995.
97. Zhu, Y.; Yang, P.; Wang, Q.; Hu, J.; Xue, J.; Li, G.; Zhang, G.; Li, X.; Li, W.; Zhou, C.; Zhao, M.; Wang, D. The effect of cxcr4 silencing on epithelial-mesenchymal transition related genes in glioma u87 cells. Anat. Rec. (Hoboken). 2013, 296(12), 1850-1856.
98. Holland, J.D.; Györffy, B.; Vogel, R.; Eckert, K.; Valenti, G.; Fang, L.; Lohneis, P.; Elezkurtaj, S.; Ziebold, U.; Birchmeier, W. Combined Wnt/β-catenin, Met, and CXCL12/CXCR4 signals characterize basal breast cancer and predict disease outcome. Cell Rep., 2013, 5(5), 1214-1227.
99. Hu, T.H.; Yao, Y.; Yu, S.; Han, L.L.; Wang, W.J.; Guo, H.; Tian, T.; Ruan, Z.P.; Kang, X.M.; Wang, J.; Wang, S.H.; Nan, K.J. SDF-1/CXCR4 promotes epithelial-mesenchymal transition and progression of colorectal cancer by activation of the Wnt/β-catenin signaling pathway. Cancer Lett., 2014, 354(2), 417-426.
100. Wang, J.; Cai, J.; Han, F.; Yang, C.; Tong, Q.; Cao, T.; Wu, L.; Wang, Z. Silencing of CXCR4 blocks progression of ovarian cancer and depresses canonical Wnt signaling pathway. Int. J. Gynecol. Cancer, 2011, 21(6), 981-987.
101. Li, X.; Ma, Q.; Xu, Q.; Liu, H.; Lei, J.; Duan, W.; Bhat, K.; Wang, F.; Wu, E.; Wang, Z. SDF-1/CXCR4 signaling induces pancreatic cancer cell invasion and epithelial-mesenchymal transition in vitro through non-canonical activation of Hedgehog pathway. Cancer Lett., 2012, 322(2), 169-176.
102. Singh, A.P.; Arora, S.; Bhardwaj, A.; Srivastava, S.K.; Kadakia, M.P.; Wang, B.; Grizzle, W.E.; Owen, L.B.; Singh, S. CXCL12/CXCR4 protein signaling axis induces sonic hedgehog expression in pancreatic cancer cells via extracellular regulated kinase-and Akt kinase-mediated activation of nuclear factor κB: implications for bidirectional tumor-stromal interactions. J. Biol. Chem., 2012, 287, 39115-3912.
103. Mirandola, L.; Apicella, L.; Colombo. M.; Yu, Y.; Berta, D.G.; Platonova, N.; Lazzari, E.; Lancellotti, M.; Bulfamante, G.; Cobos, E.; Chiriva-Internati, M.; Chiaramonte, R. Anti-Notch treatment prevents multiple myeloma cells localization to the bone marrow via the chemokine system CXCR4/SDF-1. Leukemia, 2013, 27(7), 1558-1566.
104. Wang, Y.C.; Hu, X.B.; He, F.; Feng, F.; Wang, L.; Li, W.; Zhang, P.; Li, D.; Jia, Z.S.; Liang, Y.M.; Han, H. Lipopolysaccharideinduced maturation of bone marrow-derived dendritic cells is regulated by notch signaling through the up-regulation of CXCR4. J. Biol. Chem., 2009, 284(23), 15993-16003.
105. Xie, J.; Wang, W.; Si, J.W.; Miao, X.Y.; Li, J.C.; Wang, Y.C.; Wang, Z.R.; Ma, J.; Zhao, X.C.; Li, Z.; Yi, H.; Han, H. Notch signaling regulates CXCR4 expression and the migration of mesenchymal stem cells. Cell Immunol., 2013, 281, 68-75.
106. Bertran, E.; Crosas-Molist, E.; Sancho, P.; Caja, L.; Lopez-Luque, J.; Navarro, E.; Egea, G.; Lastra, R.; Serrano, T.; Ramos, E.; Fabregat, I. Overactivation of the TGF-ttpathway confers a mesenchymal-like phenotype and CXCR4-dependent migratory properties to liver tumor cells. Hepatology, 2013, 58(6), 2032-2044.
107. Lv, B.; Yang, X.; Lv, S.; Wang, L.; Fan, K.; Shi, R.; Wang, F.; Song, H.; Ma, X.; Tan, X.; Xu, K.; Xie, J.; Wang, G.; Feng, M.; Zhang, L. CXCR4 signaling induced epithelial-mesenchymal transition by PI3K/AKT and ERK pathways in Glioblastoma. Mol. Neurobiol., 2015, 52(3), 1263-1268.
108. Yan, K.; Wu, Q.; Yan, D.H.; Lee, C.H.; Rahim, N.; Tritschler, I.; DeVecchio, J.; Kalady, M.F.; Hjelmeland, A.B.; Rich, J.N. Glioma cancer stem cells secrete Gremlin1 to promote their maintenance within the tumor hierarchy. Gen. Dev., 2014, 28(10), 1085-1100.
109. Piccirillo, S.G.; Vescovi, A.L. Bone morphogenetic proteins regulate tumorigenicity in human glioblastoma stem cells. Ernst. Schering Found. Symp. Proc. 2006, 5, 59-81.
110. Zhu, Z.; Khan, M.A.; Weiler, M.; Blaes, J.; Jestaedt, L.; Geibert, M.; Zou, P.; Gronych, J.; Bernhardt, O.; Korshunov, A.; Bugner, V.; Lichter, P.; Radlwimmer, B.; Heiland, S.; Bendszus, M.; Wick, W.; Liu, H.K. Targeting self-renewal in high-grade brain tumors leads to loss of brain tumor stem cells and prolonged survival. Cell Stem Cell, 2014, 15(2), 185-198.
111. Friedman, M.D.; Jeevan, D.S.; Tobias, M.; Murali, R.; Jhanwar-Uniyal, M. Targeting cancer stem cells in glioblastoma multiforme using mTOR inhibitors and the differentiating agent all-trans retinoic acid. Oncol Rep., 2013, 30, 1645-1650.
112. Matthay, K.K.; Reynolds, C.P.; Seeger, R.C.; Shimada, H.; Adkins, E.S.; Haas-Kogan, D.; Gerbing, R.B.; London, W.B.; Villablanca, J.G. Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: A children's oncology group study. J. Clin. Oncol., 2009, 27, 1007-1013.
113. Carpenter, R.L.; Lo, H.W. Hedgehog pathway and GLI1 isoforms in human cancer. Discov. Med., 2012, 13, 105-113.
114. Clement, V.; Sanchez, P.; De Tribolet, N.; Radovanovic, I.; Ruiz, I.; Altaba, A. HEDGEHOG-GLI1 signalling regulates human glioma growth, cancer stem cell self-renewal, and tumorigenicity. Curr. Biol., 2007, 17, 165-172.
115. Lai, K.; Kaspar, B.K.; Gage, F.H.; Schaffer, D.V.; Sonic hedgehog regulates adult neural progenitor proliferation in vitro and in vivo. Nat. Neurosci.; 2003, 6, 21-27.
116. Shi, Y.; Sun, G.; Zhao, C.; Stewart, R. Neural stem cell selfrenewal. Crit. Rev. Oncol. Hematol., 2008, 65, 43-53.
117. Zbinden, M.; Duquet, A.; Lorente-Trigos, A.; Ngwabyt, S.N.; Borges, I.; Ruiz, I.; Altaba, A. NANOG regulates glioma stem cells and is essential in vivo acting in a cross-functional network with GLI1 and p53. EMBO J., 2010, 29, 2659-2674.
118. Fareh, M.; Turchi, L.; Virolle, V.; Debruyne, D.; Almairac, F.; Dela-Forest Divonne, S.; Paquis, P.; Preynat-Seauve, O.; Krause, K.H.; Chneiweiss, H.; Virolle, T. The miR 302-367 cluster drastically affects self-renewal and infiltration properties of glioma-initiating cells through CXCR4 repression and consequent disruption of the SHH-GLI-NANOG network. Cell Death Differ., 2012, 19, 232-244.
119. Ben-Porath, I.; Thomson, M.W.; Carey, V.J.; Ge, R.; Bell, G.W.; Regev, A.; Weinberg, R.A. An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat. Genet., 2008, 40, 499-507.
120. Gruber Filbin, M.; Dabral, S.K.; Pazyra-Murphy, M.F.; Ramkissoon, S.; Kung, A.L.; Pak. E.; Chung, J.; Theisen, M.A.; Sun, Y.; Franchetti, Y.; Sun, Y.; Shulman, D.S.; Redjal. N.; Tabak, B.; Beroukhim, R.; Wang, Q.; Zhao, J.; Dorsch, M.; Buonamici, S.; Ligon, K.L.; Kelleher, J.F.; Segal. R.A. Coordinate activation of Shh and PI3K signaling in PTEN-deficient glioblastoma: New therapeutic opportunities. Nat. Med., 2013, 19(11), 1518-1523.
121. Jeter, C.R.; Liu, B.; Liu, X.; Chen, X.; Liu, C.; Calhoun-Davis, T.; Repass, J.; Zaehres, H.; Shen, J.J.; Tang, D.G. NANOG promotes cancer stem cell characteristics and prostate cancer resistance to androgen deprivation. Oncogene, 2011, 30, 3833-3845.
122. Bier, A.; Giladi, N.; Kronfeld, N.; Lee, H.K.; Cazacu, S.; Finniss, S.; Xiang, C.; Poisson, L.; De Carvalho, A.C.; Slavin, S.; Jacoby, E.; Yalon, M.; Toren, A.; Mikkelsen, T.; Brodie. C. MicroRNA-137 is downregulated in glioblastoma and inhibits the stemness of glioma stem cells by targeting RTVP-1. Oncotarget. 2013, 4, 665-676.
123. Singh, S.K.; Hawkins, C.; Clarke, I.D.; Squire, J.A.; Bayani, J.; Hide, T.; Henkelman, R.M.; Cusimano, M.D.; Dirks, P.B. Identification of human brain tumour initiating cells. Nature, 2004, 432(7015), 396-401.
124. Gelmini, S.; Mangoni, M.; Serio, M.; Romagnani, P.; Lazzeri, E. The critical role of SDF-1/CXCR4 axis in cancer and cancer stem cells metastasis. J. Endocrinol. Invest., 2008, 31, 809-889.
125. Yan, X.; Ma, L.; Yi, D.; Yoon, J.G.; Diercks, A.; Foltz, G.; Price, N.D.; Hood, L.E.; Tian, Q. A CD133-related gene expression signature identifies an aggressive glioblastoma subtype with excessive mutations. Proc. Natl. Acad. Sci. USA, 2011 108(4), 1591-1596.
126. Chen, R.; Nishimura, M.C.; Bumbaca, S.M.; Kharbanda, S.; Forrest, W.F.; Kasman, I.M.; Greve, J.M.; Soriano, R.H.; Gilmour, L.L.; Rivers, C.S.; Modrusan, Z.; Nacu, S.; Guerrero, S.; Edgar, K.A.; Wallin, J.J.; Lamszus, K.; Westphal, M.; Heim, S.; James, C.D.; VandenBerg, S.R.; Costello, J.F.; Moorefield, S.; Cowdrey, C.J.; Prados, M.; Phillips, HS. A hierarchy of self-renewing tumorinitiating cell types in glioblastoma. Cancer Cell, 2010 17(4), 362-375.
127. Venere, M.; Fine, H.A.; Dirks, PB.; Rich, J.N. Cancer stem cells in gliomas: Identifying and understanding the apex cell in cancer's hierarchy. Glia, 2011, 59, 1148-1154.
128. Florio, T.; Barbieri, F. The status of the art of human malignant glioma management: The promising role of targeting tumorinitiating cells. Drug Discov. Today, 2012, 17, 1103-1110.
129. Dunn, G.P.; Rinne, M.L.; Wykosky, J.; Genovese, G.; Quayle, S.N.; Dunn, I.F.; Agarwalla, P.K.; Chheda, M.G.; Campos, B.; Wang, A.; Brennan, C.; Ligon, K.L.; Furnari, F.; Cavenee, W.K.; Depinho, R.A.; Chin, L.; Hahn, W.C. Emerging insights into the molecular and cellular basis of glioblastoma. Gen. Dev., 2012, 26(8), 756-784.
130. Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature, 2008, 455, 1061-1068.
131. Brennan, C.; Momota, H.; Hambardzumyan, D.; Ozawa, T.; Tandon, A.; Pedraza, A.; Holland, E. Glioblastoma subclasses can be defined by activity among signal transduction pathways and associated genomic alterations. PLoS One, 2009, 4, e7752.
132. Verhaak, R.G.; Hoadley, K.A.; Purdom, E.; Wang, V.; Qi, Y.; Wilkerson, M.D.; Miller, C.R.; Ding, L.; Golub, T.; Mesirov, J.P.; Alexe, G.; Lawrence, M.; O'Kelly, M.; Tamayo, P.; Weir, B.A.; Gabriel, S.; Winckler, W.; Gupta, S.; Jakkula, L.; Feiler, H.S.; Hodgson, J.G.; James C.D; Sarkaria, J.N; Brennan, C.; Kahn, A.; Spellman, P.T.; Wilson, R.K.; Speed, T.P.; Gray, J.W.; Meyerson, M.; Getz, G.; Perou, C.M.; Hayes, D.N. Cancer Genome Atlas Research Network. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell, 2010, 17, 98-110.
133. Stommel, J.M.; Kimmelman, A.C.; Ying, H.; Nabioullin, R.; Ponugoti, A.H.; Wiedemeyer, R.; Stegh, AH.; Bradner, J.E.; Ligon, K,L.; Brennan, C.; Chin L.; DePinho, R.A. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science, 2007, 318(5848), 287-290.
134. Szerlip, N.J.; Pedraza, A.; Chakravarty, D.; Azim, M.; McGuire, J.; Fang, Y.; Ozawa, T.; Holland, E.C.; Huse, J.T.; Jhanwar, S.; Leversha, M.A.; Mikkelsen, T.; Brennan, C.W. Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response. Proc. Natl. Acad. Sci. USA, 2012, 109(8), 3041-3046.
135. Cloughesy, T.F.; Cavenee, W.K.; Mischel, P.S. Glioblastoma: From molecular pathology to targeted treatment. Annu. Rev., Pathol., 2014, 9, 1-25.
136. Griffero, F.; Daga, A.; Marubbi, D.; Capra, M.C.; Melotti, A.; Pattarozzi, A.; Gatti, M.; Bajetto, A.; Porcile, C.; Barbieri, F.; Favoni, R.E.; Lo Casto, M.; Zona, G.; Spaziante, R.; Florio, T.; Corte, G. Different response of human glioma tumor-initiatingcells to epidermal growth factor receptor kinase inhibitors. J. Biol. Chem., 2009, 284, 7138-7148.
137. Robinson, J.P.; Vanbrocklin, M.W.; McKinney, A.J.; Gach, H.M.; Holmen, S.L. Akt signaling is required for glioblastoma maintenance in vivo. Am. J. Cancer Res., 2011, 1, 155-167.
138. Moon, S.H.; Kim, D.K.; Cha, Y.; Jeon, I.; Song, J.; Park, K.S. PI3K/Akt and Stat3 signaling regulated by PTEN control of the cancer stem cell population, proliferation and senescence in a glioblastoma cell line. Int. J. Oncol., 2013, 42, 921-928.
139. Emlet, D.R, Gupta, P.; Holgado-Madruga, M.; Del Vecchio, CA.; Mitra, S.S.; Han, S.Y.; Li, G.; Jensen, K.C.; Vogel, H.; Xu, L.W.; Skirboll, S.S, Wong, A.J. Targeting a glioblastoma cancer stem-cell population defined by EGF receptor variant III. Cancer Res., 2014, 74(4), 1238-1249.
140. Porcile, C.; Bajetto, A.; Barbieri, F.; Barbero, S.; Bonavia, R.; Biglieri, M.; Pirani, P.; Florio, T.; Schettini, G. Stromal cellderived factor-1alpha (SDF-1alpha/CXCL12) stimulates ovarian cancer cell growth through the EGF receptor transactivation. Exp. Cell Res., 2005, 308, 241-253.
141. Billadeau, D.D.; Chatterjee, S.; Bramati, P.; Sreekumar, R.; Shah, V.; Hedin, K.; Urrutia, R. Characterization of the CXCR4 signaling in pancreatic cancer cells. Int. J. Gastrointest. Cancer, 2006, 37(4), 110-119.
142. Weekes, C.D.; Song, D.; Arcaroli, J.; Wilson, L.A.; Rubio-Viqueira, B.; Cusatis, G.; Garrett-Mayer, E.; Messersmith, W.A.; Winn, R.A.; Hidalgo, M. Stromal cell-derived factor 1α mediates resistance to mTOR-directed therapy in pancreatic cancer. Neoplasia, 2012, 14, 690-701.
143. Rahimi, M.; Toth, T.A.; Tang, C.K.CXCR4 suppression attenuates EGFRvIII-mediated invasion and induces p38 MAPK-dependent protein trafficking and degradation of EGFRvIII in breast cancer cells. Cancer Lett., 2011, 306(1), 43-51.
144. Phillips, R.J.; Mestas, J.; Gharaee-Kermani, M.; Burdick, M.D.; Sica, A.; Belperio, J.A, Keane, M.P, Strieter, R.M. Epidermal growth factor and hypoxia-induced expression of CXC chemokine receptor 4 on non-small cell lung cancer cells is regulated by the phosphatidylinositol 3-kinase/PTEN/AKT/mammalian target of rapamycin signaling pathway and activation of hypoxia inducible factor-1alpha. J. Biol. Chem., 2005, 280, 22473-22481.
145. Abhold, E.L.; Kiang, A.; Rahimy, E.; Kuo, S.Z.; Wang-Rodriguez, J.; Lopez, J.P.; Blair, K.J.; Yu, M.A.; Haas, M.; Brumund, K.T.; Altuna, X.; Patel, A.; Weisman, R.A.; Ongkeko, W.M. EGFR kinase promotes acquisition of stem cell-like properties: a potential therapeutic target in head and neck squamous cell carcinoma stem cells. PLoS One, 2012, 7(2), e32459.
146. Eberl, M.; Klingler, S.; Mangelberger, D.; Loipetzberger, A.; Damhofer, H.; Zoidl, K.; Schnidar, H.; Hache, H.; Bauer, HC.; Solca, F.; Hauser-Kronberger, C.; Ermilov, A.N.; Verhaegen, M.E.; Bichakjian, C.K.; Dlugosz, A.A.; Nietfeld, W.; Sibilia, M.; Lehrach, H.; Wierling, C.; Aberger F.Hedgehog-EGFR cooperation response genes determine the oncogenic phenotype of basal cell carcinoma and tumour-initiating pancreatic cancer cells. EMBO Mol. Med., 2012, 4(3), 218-233.
147. Woerner, B.M.; Luo, J.; Brown, K.R.; Jackson, E.; Dahiya, S.M.; Mischel, P.; Benovic, J.L.; Piwnica-Worms, D.; Rubin, J.B. Suppression of G-protein-coupled receptor kinase 3 expression is a feature of classical GBM that is required for maximal growth. Mol. Cancer Res., 2012, 10(1), 156-166.
148. Busillo, J.M.; Armando, S.; Sengupta, R.; Meucci, O.; Bouvier, M.; Benovic, J.L. Site-specific phosphorylation of CXCR4 is dynamically regulated by multiple kinases and results in differential modulation of CXCR4 signaling. J. Biol. Chem., 2010, 285(10), 7805-7817.
149. Yuan, L.; Zhang, H.; Liu, J.; Rubin, J.B.; Cho, Y.J.; Shu, H.K.; Schniederjan, M.; MacDonald, T.J. Growth factor receptor-Srcmediated suppression of GRK6 dysregulates CXCR4 signaling and promotes medulloblastoma migration. Mol. Cancer, 2013, 12, 18.
150. Liu, J.; Liao, S.; Huang, Y.; Samuel, R.; Shi, T.; Naxerova, K.; Huang, P.; Kamoun, W.; Jain, R.K.; Fukumura, D.; Xu, L. PDGFD improves drug delivery and efficacy via vascular normalization, but promotes lymphatic metastasis by activating CXCR4 in breast cancer. Clin. Cancer Res., 2011, 17(11), 3638-3648.
151. Hamdan, R.; Zhou, Z.; Kleinerman, E.S. Blocking SDF-1α/CXCR4 downregulates PDGF-B and inhibits bone marrow-derived pericyte differentiation and tumor vascular expansion in Ewing tumors. Mol. Cancer Ther., 2014, 13(2), 483-491.
152. Song, N.; Huang, Y.; Shi, H.; Yuan, S.; Ding, Y.; Song, X.; Fu, Y.; Luo, Y. Overexpression of platelet-derived growth factor-BB increases tumor pericyte content via stromal-derived factor-1alpha/CXCR4 axis. Cancer Res., 2009, 69, 6057-6064.
153. Esencay, M.; Newcomb, E.W.; Zagzag, D. HGF upregulates CXCR4 expression in gliomas via NF-kappaB: Implications for glioma cell migration. J. Neurooncol., 2010, 99, 33-40.
154. Tu, H.; Zhou, Z.; Liang, Q.; Li, Z.; Li, D.; Qing, J.; Wang, H.; Zhang, L. CXCR4 and SDF-1 production are stimulated by hepatocyte growth factor and promote glioma cell invasion. Onkologie, 2009, 32(6), 331-336.
155. Huang, S.; Ouyang, N.; Lin, L.; Chen, L.; Wu, W.; Su, F.; Yao, Y, Yao, H. HGF-induced PKCζ activation increases functional CXCR4 expression in human breast cancer cells. PLoS One, 2012, 7(1), e29124.
156. Majka, M.; Drukala, J.; Lesko, E.; Wysoczynski, M.; Jenson, A.B.; Ratajczak, M.Z. SDF-1 alone and in co-operation with HGF regulates biology of human cervical carcinoma cells. Folia Histochem. Cytobiol., 2006, 44(3), 155-164.
157. Rø, T.B, Holien, T.; Fagerli, U.M.; Hov, H.; Misund, K.; Waage, A.; Sundan, A.; Holt, R.U.; Børset, M. HGF and IGF-1 synergize with SDF-1α in promoting migration of myeloma cells by cooperative activation of p21-activated kinase. Exp Hematol., 2013, 41(7), 646-655.
158. Mehta, S.A, Christopherson, K.W.; Bhat-Nakshatri, P.; Goulet, R.J. Jr.; Broxmeyer, H.E.; Kopelovich, L.; Nakshatri, H. Negative regulation of chemokine receptor CXCR4 by tumor suppressor p53 in breast cancer cells: implications of p53 mutation or isoform expression on breast cancer cell invasion. Oncogene, 2007, 26(23), 3329-3337.
159. Mo, W.; Chen, J.; Patel, A.; Zhang, L.; Chau, V.; Li, Y.; Cho, W.; Lim, K.; Xu, J.; Lazar, A.J.; Creighton, C.J.; Bolshakov, S.; McKay, R.M.; Lev, D.; Le, L.Q.; Parada, L.F. CXCR4/CXCL12 mediate autocrine cell-cycle progression in NF1-associated malignant peripheral nerve sheath tumors. Cell, 2013, 152(5), 1077-1090.
160. Zhao, M.; Discipio, R.G.; Wimmer, A.G.; Schraufstatter, I.U. Regulation of CXCR4-mediated nuclear translocation of extracellular signal-related kinases 1 and 2. Mol. Pharmacol., 2006, 69(1), 66-75.
161. Chinni, S.R.; Yamamoto, H.; Dong, Z.; Sabbota, A.; Bonfil, R.D.; Cher, M.L. CXCL12/CXCR4 transactivates HER2 in lipid rafts of prostate cancer cells and promotes growth of metastatic deposits in bone. Mol. Cancer Res., 2008 6(3), 446-457.
162. Salinas-Souza, C.; De Oliveira, R.; Alves, MT.; Garcia Filho, R.J.; Petrilli, A.S.; Toledo, S.R. The metastatic behavior of osteosarcoma by gene expression and cytogenetic analyses. Hum. Pathol., 2013, 44(10), 2188-2198.
163. Brooks, M.D.; Sengupta, R.; Snyder, S.C.; Rubin, J.B. Hitting them where they live: targeting the glioblastoma perivascular stem cell niche. Curr. Pathobiol. Rep., 2013, 1, 101-110.
164. Rao, S.; Sengupta, R.; Choe, E.J.; Woerner, B.M.; Jackson, E.; Sun, T.; Leonard, J.; Piwnica-Worms, D.; Rubin, J.B. CXCL12 mediates trophic interactions between endothelial and tumor cells in glioblastoma. PLoS One, 2012, 7(3), e33005.
165. Wang, R.; Chadalavada, K.; Wilshire, J.; Kowalik, U.; Hovinga, KE.; Geber, A.; Fligelman, B.; Leversha M.; Brennan, C.; Tabar, V. Glioblastoma stem-like cells give rise to tumour endothelium. Nature, 2010, 468, 829-833.
166. Ricci-Vitiani, L.; Pallini, R.; Biffoni, M.; odaro, M.; Invernici, G.; Cenci, T.; Maira, G.; Parati, EA.; Stassi, G.; Larocca, L.M.; De Maria, R. Tumour vascularization via endothelial differentiation of glioblastoma stemlike cells. Nature, 2010, 468, 824-828.
167. Soda, Y.; Marumoto, T.; Friedmann-Morvinski, D.; Soda, M.; Liu, F.; Michiue, H.; Pastorino, S.; Yang, M.; Hoffman, R.M.; Kesari, S.; Verma, I.M. Transdifferentiation of glioblastoma cells into vascular endothelial cells. Proc. Natl. Acad. Sci. USA, 2011, 108, 4274-4280.
168. Abdullah, L.N.; Chow, E.K. Mechanisms of chemoresistance in cancer stem cells. Clin. Transl. Med. 2013, 2, 3.
169. Quintavalle, C.; Mangani, D.; Roscigno, G.; Romano, G.; Diaz-Lagares, A.; Iaboni, M.; Donnarumma, E.; Fiore, D.; De Marinis, P.; Soini, Y.; Esteller, M.; Condorelli, G. miR-221/222 Target the DNA Methyltransferase MGMT in Glioma Cells. PLoS One, 2013, 8, e7446.
170. Bao, S.; Wu, Q.; McLendon, R.E.; Hao, Y.; Shi, Q.; Hjelmeland, A.B.; Dewhirst, M.W.; Bigner, D.D.; Rich, J.N. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature, 2006, 444, 756-760.
171. Chen, Y.; Jacamo, R.; Konopleva, M.; Garzon, R.; Croce, C.; Andreeff, M. CXCR4 downregulation of let-7a drives chemoresistance in acute myeloid leukemia. J. Clin. Invest, 2013, 123, 2395-2407.
172. Mantoni, T.S.; Lunardi, S.; Al-Assar, O.; Masamune, A.; Brunner, T.B. Pancreatic Stellate Cells Radioprotect Pancreatic Cancer Cells through {beta}1-Integrin Signaling. Cancer Res., 2011, 71, 3453-3458.
173. Soeda, A.; Park, M.; Lee, D.; Mintz, A.; Androutsellis-Theotokis, A.; McKay, R.D.; Engh, J.; Iwama, T.; Kunisada, T.; Kassam, A.B.; Pollack, I.F.; Park, D.M. Hypoxia promotes expansion of the CD133-positive glioma stem cells through activation of HIF-1alpha. Oncogene, 2009, 28, 3949-3959.
174. Croker, A.K.; Allan, A.L. Cancer stem cells: Implications for the progression and treatment of metastatic disease. J. Cell Mol. Med., 2008, 12, 374-390.
175. Batchelor, T.T.; Sorensen, A.G.; Di Tomaso, E.; Zhang, W.T.; Duda, D.G.; Cohen, K.S.; Kozak, K.R.; Cahill, D.P.; Chen, P.J.; Zhu, M.; Ancukiewicz, M.; Mrugala, M.M.; Plotkin, S.; Drappatz, J.; Louis, D.N.; Ivy, P.; Scadden, D.T.; Benner, T.; Loeffler, J.S.; Wen, P.Y.; Jain, R.K. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell, 2007,11, 83-95.
176. Xu, L.; Duda, D.G.; Di Tomaso, E.; Ancukiewicz, M.; Chung, D.C.; Lauwers, G.Y.; Samuel, R.; Shellito, P.; Czito, B.G.; Lin, P.C.; Poleski, M.; Bentley, R.; Clark, J.W.; Willett, C.G.; Jain, R.K. Direct evidence that bevacizumab, an anti-VEGF antibody, up-regulates SDF-1alpha, CXCR4, CXCL6, and neuropilin 1 in tumors from patients with rectal cancer. Cancer Res., 2009, 69, 7905-7910.
177. Liu, S.C.; Alomran, R.; Chernikova, S.B.; Lartey, F.; Stafford, J.; Jang, T.; Merchant, M.; Zboralski, D.; Zöllner, S.; Kruschinski, A.; Klussmann, S.; Recht, L.; Brown, J.M. Blockade of SDF-1 after irradiation inhibits tumor recurrences of autochthonous brain tumors in rats. Neuro. Oncol., 2014 16(1), 21-28.
178. Batchelor, T.T.; Duda, D.G.; Di Tomaso, E.; Ancukiewicz, M.; Plotkin, S.R.; Gerstner, E.; Eichler, A.F.; Drappatz, J.; Hochberg, F.H.; Benner, T.; Louis, D.N.; Cohen, K.S.; Chea, H.; Exarhopoulos, A.; Loeffler, J.S.; Moses, M.A.; Ivy, P.; Sorensen, A.G.; Wen, P.Y.; Jain, R.K. Phase II study of cediranib, an oral pan-VEGF receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J. Clin. Oncol., 2010, 28, 2817-2823.
179. Gerstner, E.R.; Eichler, A.F.; Plotkin, S.; Drappatz, J.; Doyle, C.L.; Xu, L.; Duda, D.G.; Wen, P.Y.; Jain, R.K.; Batchelor, T.T. Phase I study of vatalanib (PTK787) patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomide. J. Neurooncol., 2011, 103, 325-332.
180. Raut, C.P.; Boucher, Y.; Duda, D.G.; Morgan, J.A.; Quek, R.; Ancukiewicz, M.; Lahdenranta, J.; Eder, J.P.; Demetri, G.D.; Jain, R.K. Effects of sorafenib on intra-tumoral interstitial fluid pressure and circulating biomarkers in patients with refractory sarcomas (NCI protocol 6948). PLoS One, 2012, 7, e26331.
181. Liang, Z.; Brooks, J.; Willard, M.; Liang, K.; Yoon, Y.; Kang, S.; Shim, H. CXCR4/CXCL12 axis promotes VEGF-mediated tumor angiogenesis through Akt signaling pathway. Biochem. Biophys. Res. Commun., 2007, 359(3), 716-722.
182. Sun, X.; Charbonneau, C.; Wei, L.; Yang, W.; Chen, Q.; Terek, R.M. CXCR4-Targeted therapy inhibits vegf expression and chondrosarcoma angiogenesis and metastasis. Mol. Cancer Ther., 2013, 12, 1163-1170.
183. Hiratsuka, S.; Duda, D.G.; Huang, Y.; Goel, S.; Sugiyama, T.; Nagasawa, T.; Fukumura, D.; Jain, R.K. C-X-C receptor type 4 promotes metastasis by activating p38 mitogen-activated protein kinase in myeloid differentiation antigen (Gr-1)-positive cells. Proc. Natl .Acad. Sci. USA, 2011, 108, 302-307.
184. Kozin, S.V.; Kamoun, W.S.; Huang, Y.; Dawson, M.R.; Jain, R.K.; Duda, D.G. Recruitment of myeloid but not endothelial precursor cells facilitates tumor regrowth after local irradiation. Cancer Res., 2010, 70, 5679-5685.
185. Kioi, M.; Vogel, H.; Schultz, G.; Hoffman, R.M.; Harsh, G.R.; Brown, J.M. Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice. J . Clin. Invest., 2010, 120, 694-705.
186. Azab, A.K.; Runnels, J.M.; Pitsillides, C.; Moreau, A.S.; Azab, F.; Leleu, X.; Jia, X.; Wright, R.; Ospina, B.; Carlson, A.L.; Alt, C.; Burwick, N.; Roccaro, A.M.; Ngo, H.T.; Farag, M.; Melhem, M.R.; Sacco, A.; Munshi, N.C.; Hideshima, T.; Rollins, B.J.; Anderson, K.C.; Kung, A.L.; Lin, C.P.; Ghobrial, I.M. CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. Blood, 2009, 113, 4341-4351.
187. Zeng, Z.; Samudio, I.J.; Munsell, M.; An, J.; Huang, Z.; Estey, E.; Andreeff, M.; Konopleva, M. Inhibition of CXCR4 with the novel RCP168 peptide overcomes stroma-mediated chemoresistance in chronic and acute leukemias. Mol. Cancer Ther., 2006, 5, 3113-3121.
188. Murakami, J.; Li, T.S.; Ueda, K.; Tanaka, T.; Hamano, K. Inhibition of accelerated tumor growth by blocking the recruitment of mobilized endothelial progenitor cells after chemotherapy. Int. J. Cancer, 2009, 124, 1685-1692.
189. Uy, G.L.; Rettig, M.P.; Motabi, I.H.; McFarland, K.; Trinkaus, K.M.; Hladnik, L.M.; Kulkarni, S.; Abboud, C.N.; Cashen, A.F.; Stockerl-Goldstein, K.E.; Vij, R.; Westervelt, P.; DiPersio, J.F. A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia. Blood, 2012, 119(17), 3917-3924.
190. Redjal, N.; Chan, J.A.; Segal, R.A.; Kung, A.L. CXCR4 inhibition synergizes with cytotoxic hemotherapy in gliomas. Clin. Cancer Res., 2006, 12, 6765-6771.
191. Dubrovska, A.; Hartung, A.; Bouchez, L.C.; Walker, J.R.; Reddy, V.A.; Cho, C.Y.; Schultz, P.G. CXCR4 activation maintains a stem cell population in tamoxifen-resistant breast cancer cells through AhR signalling. Br. J. Cancer, 2012, 107, 43-52.
192. Hatano, K.; Yamaguchi, S.; Nimura, K.; Murakami, K.; Nagahara, A.; Fujita, K.; Uemura, M.; Nakai, Y.; Tsuchiya, M.; Nakayama, M.; Nonomura, N.; Kaneda, Y. Residual prostate cancer cells after docetaxel therapy increase the tumourigenic potential via constitutive CXCR4, ERK1/2 and c-Myc signalling loop activation. Mol. Cancer Res., 2013, 11(9),1088-1100.
193. Heckmann, D.; Maier, P.; Laufs, S.; Wenz, F.; Zeller, WJ.; Fruehauf, S.; Allgayer, H. CXCR4 expression and treatment with SDF-1α or plerixafor modulate proliferation and chemosensitivity of colon cancer cells. Transl. Oncol., 2013, 6, 124-132.
194. Hartmann, T.N.; Burger, J.A.; Glodek, A.; Fujii, N.; Burger, M. CXCR4 chemokine receptor and integrin signaling co-operate in mediating adhesion and chemoresistance in small cell lung cancer (SCLC) cells. Oncogene, 2005, 24, 4462-4471.
195. Bertolini, G.; Roz, L.; Perego, P.; Tortoreto, M.; Fontanella, E.; Gatti, L.; Pratesi, G.; Fabbri, A.; Andriani, F.; Tinelli, S.; Roz, E.; Caserini, R.; Lo Vullo, S.; Camerini, T.; Mariani, L.; Delia, D.; Calabrò, E.; Pastorino, U.; Sozzi, G. Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment. Proc. Natl. Acad. Sci. USA, 2009, 106, 16281-16286.
196. Fahham, D.; Weiss, I.D.; Abraham, M.; Beider, K.; Hanna, W.; Shlomai, Z.; Eizenberg, O.; Zamir, G.; Izhar, U.; Shapira, O.M.; Peled, A.; Wald, O. in vitro and in vivo therapeutic efficacy of CXCR4 antagonist BKT140 against human non-small cell lung cancer. J. Thorac. Cardiovasc. Surg., 2012, 144, 1167-1175.
197. Arora, S.; Bhardwaj, A.; Singh, S.; Srivastava, S.K.; McClellan, S.; Nirodi, C.S.; Piazza, G.A.; Grizzle, W.E.; Owen, L.B.; Singh, A.P. An undesired effect of chemotherapy: Gemcitabine promotes pancreatic cancer cell invasiveness through ROS dependent NFkB and HIF-1HHmediated up regulation of CXCR4. J. Biol. Chem., 2013, 288, 21197-21207.
198. Singh, S.; Srivastava, S.K.; Bhardwaj, A.; Owen, L.B.; Singh, A.P. CXCL12-CXCR4 signalling axis confers gemcitabine resistance to pancreatic cancer cells: A novel target for therapy. Br. J. Cancer, 2010, 103, 1671-1679.
199. Domanska, U.M.; Timmer-Bosscha, H.; Nagengast, W.B.; Oude Munnink, T.H.; Kruizinga, R.C.; Ananias, H.J.; Kliphuis, N.M.; Huls, G.; De Vries, E.G.; De Jon,. I.J.; Walenkamp, A.M. CXCR4 inhibition with AMD3100 sensitizes prostate cancer to docetaxel chemotherapy. Neoplasia, 2012, 14, 709-718.
200. Sison, E.A.; McIntyre, E.; Magoon, D.; Brown, P. Dynamic chemotherapy-induced upregulation of surface CXCR4 expression as a mechanism of chemotherapy resistance in pediatric acute myeloid leukemia. Mol. Cancer Res., 2013, 11, 1004-1016.
201. Portella, L.; Vitale, R.; De Luca, S.; D'Alterio, C.; Ieranò, C.; Napolitano, M.; Riccio, A.; Polimeno, M.N.; Monfregola, L.; Barbieri, A.; Luciano, A.; Ciarmiello, A.; Arra, C.; Castello, G.; Amodeo, P.; Scala, S. Preclinical development of a novel class of CXCR4 antagonist impairing solid tumors growth and metastases. PLoS One, 2013, 8(9), e74548.
202. Mungalpara, J.I.; Zachariassen, Z.G.; Thiele, S.; Rosenkilde, M.M.; Våbenø, J. Structure-activity relationship studies of the aromatic positions in cyclopentapeptide CXCR4 antagonists. Org. Biomol. Chem., 2013 11(47), 8202-8208.
203. Vitale, R.M.; Gatti, M.; Carbone, M.; Barbieri, F.; Felicità, V.; Gavagnin, M.; Florio, T.; Amodeo, P. Minimalist hybrid ligand/receptor-based pharmacophore model for CXCR4 applied to a small-library of marine natural products led to the identification of phidianidine a as a new CXCR4 ligand exhibiting antagonist activity. ACS Chem. Biol., 2013, 8(12), 2762-2770.
204. Phillips, T.M.; McBride, W.H.; Pajonk, F. The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation. J. Natl. Cancer Inst., 2006, 98, 1777-1785.